EDGAR·FLOW

Aligos Therapeutics, Inc. — Form 10-Q

Filed November 6, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 72/100
What the filing says
Aligos Therapeutics extended its lease at One Corporate Drive, South San Francisco (38,675 sq ft, entire 2nd floor) from expiring March 31, 2027 to March 31, 2034 (84 months). Base rent escalates from $2.16M annually (year 1) to $2.65M (year 7); tenant receives 10 months of base rent abatement plus $773,500 refurbishment allowance ($20/sq ft). Counterparty: Britannia Biotech Gateway Limited Partnership (landlord). Tenant gains ROFR on 1st floor space and ROFO on adjacent building 2 Corp Drive, plus early termination option at March 31, 2031 for $2.48M.
Why this rating

Lease extension locks in ~$18.7M cumulative rent obligation vs. $19.9M market cap; material but non-transformational. 10-month abatement and $773.5K allowance reduce cash outlay. Early termination optionality mitigates downside. Routine real estate restructuring for a pre-revenue biotech.

Price action (we called it neutral)
at our read · unknown
$4.44
+10 min · unknown
$4.44 ▲ 0.00%
+30 min · unknown
$4.44 ▲ 0.00%
+1 hr · unknown
$4.49 ▲ 1.13%
+4 hrs · unknown
$4.25 ▼ 4.19%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ALGS · stock on Yahoo Finance ↗

See more from November 6, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.